David Anstice - Alkermes Plc Independent Director

ALKS Stock  USD 27.07  0.18  0.66%   

Director

Mr. David W. Anstice is Independent Director of the Company. From 2006 until his retirement in 2008, Mr. Anstice served as Executive Vice President of Merck, with responsibility for enterprise strategy and implementation. During two separate parts of this period he was acting President, Global Human Health and President of Mercks business in Japan. From 2003 to 2006, Mr. Anstice served as President of Merck, with responsibility for Mercks Asia Pacific businesses. In his 34 years with Merck, he held a variety of positions including President, U.S. Human Health President, Human Health, the Americas President, U.S.Canada and President, Human Health, Europe. He reported to the Merck CEO from 1994 until his retirement in 2008. Mr. Anstice is currently a director of CSL Limited, a global specialty biopharmaceutical company and a director of the private company NeuClone Pharmaceuticals Pty Ltd., a cell line production company. Mr. Anstice is also Chairman and President of the board for the University of Sydney USA Foundation, Vice Chairman and a member of the board of the U.S. Studies Centre at the University of Sydney, Australia, a member of the U.S. Advisory Council of the American Australian Association in New York, and an Adjunct Professor at the University of Sydney Business School. since 2011.
Age 69
Tenure 13 years
Address Connaught House, Dublin, Ireland, D04 C5Y6
Phone353 1 772 8000
Webhttps://www.alkermes.com
Anstice is Chairman and President of the board for the University of Sydney USA Foundation, a member of the board of the U.S. Studies Centre based at the University of Sydney, Australia and the Board of USA Foundation of the University of the Valley of Guatemala, a member of the U.S. Advisory Council for the American Australian Association in New York, a director of CSL Limited, a global specialty biopharmaceutical company, and an Adjunct Professor at the University of Sydney Business School.

Alkermes Plc Management Efficiency

The company has return on total asset (ROA) of 0.1281 % which means that it generated a profit of $0.1281 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.4622 %, meaning that it created $0.4622 on every $100 dollars invested by stockholders. Alkermes Plc's management efficiency ratios could be used to measure how well Alkermes Plc manages its routine affairs as well as how well it operates its assets and liabilities. Return On Capital Employed is likely to gain to 0.27 in 2024. Return On Assets is likely to gain to 0.17 in 2024. At this time, Alkermes Plc's Total Assets are comparatively stable compared to the past year. Non Currrent Assets Other is likely to gain to about 165.2 M in 2024, whereas Other Assets are likely to drop 0.95 in 2024.
The company currently holds 290.73 M in liabilities with Debt to Equity (D/E) ratio of 0.38, which is about average as compared to similar companies. Alkermes Plc has a current ratio of 2.33, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Alkermes Plc until it has trouble settling it off, either with new capital or with free cash flow. So, Alkermes Plc's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Alkermes Plc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Alkermes to invest in growth at high rates of return. When we think about Alkermes Plc's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Raymond OConorArrow Financial
62
Matthew PaullChipotle Mexican Grill
67
Gary DakeArrow Financial
57
Peter RothschildThe Wendys Co
62
Albert BaldocchiChipotle Mexican Grill
67
Kristin DolanThe Wendys Co
51
Elizabeth MillerArrow Financial
64
Mark BehanArrow Financial
57
Michael BuffingtonJuniata Valley Financial
N/A
Randolph LewisThe Wendys Co
64
John MurphyArrow Financial
62
Gary KelseyJuniata Valley Financial
54
Patrick FlynnChipotle Mexican Grill
72
Darlene FriedmanChipotle Mexican Grill
72
Charles HershbergerJuniata Valley Financial
68
Jan SnedekerJuniata Valley Financial
67
Ali NamvarChipotle Mexican Grill
50
Michael ClarkeArrow Financial
71
John CharlesworthChipotle Mexican Grill
68
Neil FlanzraichChipotle Mexican Grill
76
Elizabeth LittleArrow Financial
73
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland. Alkermes Plc operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 2211 people. Alkermes Plc (ALKS) is traded on NASDAQ Exchange in USA. It is located in Connaught House, Dublin, Ireland, D04 C5Y6 and employs 2,100 people. Alkermes Plc is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Alkermes Plc Leadership Team

Elected by the shareholders, the Alkermes Plc's board of directors comprises two types of representatives: Alkermes Plc inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alkermes. The board's role is to monitor Alkermes Plc's management team and ensure that shareholders' interests are well served. Alkermes Plc's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alkermes Plc's outside directors are responsible for providing unbiased perspectives on the board's policies.
Peter Norman, Senior Relations
David Gaffin, Senior Vice President Chief Legal Officer
Richard Pops, Chairman and CEO
Iain Brown, Chief Accounting Officer
Craig Hopkinson, Senior Vice President - Clinical Development and Medical Affairs, Chief Medical Officer
Gordon Pugh, COO, Senior Vice President Chief Risk Officer
Nancy Snyderman, Director
Declan OConnor, Health Environment
James Robinson, COO
Michael Landine, Senior Vice President - Corporate Development
Thomas Harvey, Chief IT
James Frates, CFO, Sr. VP and Treasurer
Craig MD, Executive Officer
Floyd MD, Founder
Nancy Wysenski, Director
Mark Stejbach, Senior Vice President Chief Commercial Officer
Shane Cooke, President
Sandra Coombs, Senior Relations
Mark Namchuk, Senior Vice President - Research, Pharmaceutical and Non-Clinical Development
Rebecca Peterson, Senior Vice President
Floyd Bloom, Independent Director
Kathryn Biberstein, Chief Compliance Officer, Chief Legal Officer, Sr. VP and Secretary
Robert Breyer, Independent Director
Wendy Dixon, Independent Director
Blair Jackson, Executive Officer
David Anstice, Independent Director
Paul Mitchell, Lead Independent Director
Elliot Ehrich, Senior Vice President - Research and Development, Chief Medical Officer
Samuel Parisi, Interim Finance
CTodd Nichols, Senior Vice President of Sales and Marketing
Stephen Schiavo, Senior Resources

Alkermes Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alkermes Plc a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Pair Trading with Alkermes Plc

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Alkermes Plc position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Alkermes Plc will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Alkermes Plc could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Alkermes Plc when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Alkermes Plc - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Alkermes Plc to buy it.
The correlation of Alkermes Plc is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Alkermes Plc moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Alkermes Plc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Alkermes Plc can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Alkermes Plc is a strong investment it is important to analyze Alkermes Plc's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Alkermes Plc's future performance. For an informed investment choice regarding Alkermes Stock, refer to the following important reports:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alkermes Plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in industry.
For more information on how to buy Alkermes Stock please use our How to Invest in Alkermes Plc guide.
You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.

Complementary Tools for Alkermes Stock analysis

When running Alkermes Plc's price analysis, check to measure Alkermes Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alkermes Plc is operating at the current time. Most of Alkermes Plc's value examination focuses on studying past and present price action to predict the probability of Alkermes Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alkermes Plc's price. Additionally, you may evaluate how the addition of Alkermes Plc to your portfolios can decrease your overall portfolio volatility.
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Is Alkermes Plc's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alkermes Plc. If investors know Alkermes will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alkermes Plc listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
3.06
Revenue Per Share
10.007
Quarterly Revenue Growth
0.239
Return On Assets
0.1281
Return On Equity
0.4622
The market value of Alkermes Plc is measured differently than its book value, which is the value of Alkermes that is recorded on the company's balance sheet. Investors also form their own opinion of Alkermes Plc's value that differs from its market value or its book value, called intrinsic value, which is Alkermes Plc's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alkermes Plc's market value can be influenced by many factors that don't directly affect Alkermes Plc's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alkermes Plc's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alkermes Plc is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alkermes Plc's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.